Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics has released a new commercial assessment for its lead drug candidate ATH434, aimed at treating Multiple System Atrophy (MSA), estimating potential global peak sales at USD $2.4 billion. The assessment, based on positive Phase 2 trial results, indicates strong interest from neurologists, with over 70% likely to prescribe ATH434 due to its efficacy in slowing disease progression and stabilizing symptoms, positioning Alterity favorably in the neurodegenerative treatment market.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Its primary product, ATH434, targets conditions like Multiple System Atrophy (MSA) and Parkinson’s disease by inhibiting the aggregation of pathological proteins.
YTD Price Performance: 10.0%
Average Trading Volume: 14,065,103
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$103.3M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.